And

are now a part of the new and improved

Advertisement

Dermwire News

News | April 11, 2019

Alastin’s TransFORM Body Treatment May Enhance Cryolipolyis Outcomes

Alastin’s TransFORM Body Treatment with TriHex Technology may accelerate outcomes seen with cryolipolysis, according to new research in the Journal of Drugs in Dermatology. In a double-blind randomized controlled clinical trial,...

Read More

News | April 19, 2019

Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapy

Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic...

Read More

News | April 15, 2019

AAD Honors Dr. Robert Brodell for Establishing Free Clinic in the Mississippi Delta

Robert T. Brodell, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for working with colleagues at the University of Mississippi Medical Center in Oxford to open a dermatology clinic in the Delta — an area of...

Read More

News | March 28, 2019

BTL to Launch Small Emsculpt Applicator for Arms, Thighs, Calves

BTL is rolling out a small Emsculpt applicator to treat arms, thighs and calves at the annual meeting of the American Society for Laser Medicine and Surgery in Denver. Until now, there were only protocols for the abdominals and...

Read More
Thumbnail for gvhiwine
Play Button

Updates from Principia, Sebacia, and Candela

Series: DermWire TV | March 21, 2019

Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranded to reflect the unification of the Syneron and Candela brands. Dupixent from Regeneron Pharmaceuticals and Sanofi is now approved to treat atopic dermatitis in patients ages 12 through 17.

Watch Video

Advertisement

The Latest News

Advertisement

View more

Advertisement